Eli Lilly and Company (NYSE:LLY) Shares Sold by CENTRAL TRUST Co

CENTRAL TRUST Co trimmed its holdings in Eli Lilly and Company (NYSE:LLYFree Report) by 1.3% during the first quarter, Holdings Channel.com reports. The fund owned 45,621 shares of the company’s stock after selling 589 shares during the period. Eli Lilly and Company accounts for 0.9% of CENTRAL TRUST Co’s investment portfolio, making the stock its 29th largest holding. CENTRAL TRUST Co’s holdings in Eli Lilly and Company were worth $35,491,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. V Square Quantitative Management LLC grew its position in shares of Eli Lilly and Company by 37.0% in the first quarter. V Square Quantitative Management LLC now owns 12,781 shares of the company’s stock valued at $9,943,000 after purchasing an additional 3,453 shares during the last quarter. Activest Wealth Management acquired a new stake in Eli Lilly and Company during the 1st quarter valued at $39,000. Oxler Private Wealth LLC increased its position in Eli Lilly and Company by 217.1% during the first quarter. Oxler Private Wealth LLC now owns 6,012 shares of the company’s stock worth $4,677,000 after buying an additional 4,116 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Eli Lilly and Company in the first quarter worth $2,530,000. Finally, Demars Financial Group LLC lifted its position in shares of Eli Lilly and Company by 31.0% in the first quarter. Demars Financial Group LLC now owns 757 shares of the company’s stock valued at $589,000 after acquiring an additional 179 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Bank of America boosted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday, April 30th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Finally, JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $769.53.

Get Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Trading Up 2.7 %

LLY stock traded up $20.79 during midday trading on Tuesday, reaching $803.97. 4,332,839 shares of the company’s stock traded hands, compared to its average volume of 3,018,441. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $816.61. The business has a 50-day moving average price of $762.62 and a two-hundred day moving average price of $689.24. The company has a market capitalization of $764.10 billion, a P/E ratio of 118.41, a PEG ratio of 1.52 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the prior year, the company earned $1.62 EPS. The firm’s revenue was up 26.0% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.